Confirmed that the therapeutic efficacy of SM17 for treating AD is comparable to that of JAK1 inhibitor with good tolerability and safety HONG KONG, Apr 16, 2024 – (ACN Newswire) – SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases, is pleased to announce that the preclinical works of SM17, a humanised IgG4 monoclonal antibody against IL-17RB, is published on Allergy, an official journal of…
